Family History Of Prostate Cancer Research Articles

Abstract 6489: Marital status, living arrangement, and overall survival among individuals with advanced prostate cancer in the IRONMAN cohort

Abstract Background: More than 100,000 individuals in the United States are survivors of advanced prostate cancer, defined as metastatic hormone sensitive (mHSPC) or castration resistant prostate cancer (CRPC). This growing, vulnerable population could be uniquely susceptible or responsive to factors that are associated with overall survival. We investigated the associations of marital status and living arrangements with overall survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer (IRONMAN). Methods: We included 2,347 men (ages 40-96 years, median 70 years) with advanced prostate cancer recruited between 2017 and October 2022. Cox proportional hazards models estimated adjusted hazard ratios (adjusted HR) and 95% confidence intervals (CI) for the associations between marital status (married vs. not married), living arrangement (living alone vs. not living alone) and all-cause mortality, mutually adjusting for marital status and living arrangement and potential confounders (disease state [mHSPC vs. CRPC], country of enrollment, age at enrollment, race, education, employment status, smoking status, family history of prostate cancer, prostate specific antigen level at enrollment, and Gleason score). We conducted stratified analyses by disease state (mHSPC vs. CRPC), age (<70 vs. ≥70 years), and country of enrollment (North America vs. others). Results: This study included 1524 (65%) participants with mHSPC and 809 (35%) with CRPC. 1690 (77%) were married and 338 (16%) lived alone. Over the follow-up period (maximum: 52 months, median: 6 months, IQR: 13 months), we observed 451 deaths, with 313 deaths among married individuals and 59 deaths among those who lived alone. Overall, married individuals had better survival compared to those not married (adjusted HR: 0.52; 95% CI 0.35, 0.78), while those living alone had better survival compared to those not living alone (adjusted HR: 0.48; 95% CI: 0.29, 0.80). The protective association between being married and survival is stronger among those with mHSPC (adjusted HR: 0.42; 95% CI: 0.24, 0.71) compared to those with CRPC (adjusted HR: 0.72; 95% CI: 0.35, 1.49) and stronger among those with ages 70 or older (adjusted HR: 0.43; 95% CI: 0.25, 0.74) compared to those younger than 70 (adjusted HR: 0.71; 95% CI: 0.36, 1.43). Conclusion: Being married was associated with better survival among advanced prostate cancer survivors. While living alone was also associated with better survival, this finding should be interpreted with caution as there may be residual confounding by socioeconomic status or physical functioning. Citation Format: Naiyu Chen, Colleen B. McGrath, Caroline I. Ericsson, Jane B. Vaselkiv, Michelle O. Sodipo, Emily M. Rencsok, Konrad H. Stopsack, Daniel J. George, Karen A. Autio, Dana E. Rathkopf, Kathryn L. Penney, Lorelei A. Mucci. Marital status, living arrangement, and overall survival among individuals with advanced prostate cancer in the IRONMAN cohort. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6489.

MP44-20 MALE-CARRIERS OF GENE MUTATIONS ASSOCIATED WITH INCREASED RISK OF PROSTATE CANCER: RESULTS FROM A SINGLE INSTITUTION GENETIC COUNSELING CONSULTATION

You have accessJournal of UrologyCME1 Apr 2023MP44-20 MALE-CARRIERS OF GENE MUTATIONS ASSOCIATED WITH INCREASED RISK OF PROSTATE CANCER: RESULTS FROM A SINGLE INSTITUTION GENETIC COUNSELING CONSULTATION Estefania Linares-Espinós, Leticia Ruiz-Gimenez, Emilio Rios, Dario Sánchez-Cabrero, Elisa York Pineda, Asier Leibar, Jose María Alonso-Dorrego, and Luis Martínez-Piñeiro Estefania Linares-EspinósEstefania Linares-Espinós More articles by this author , Leticia Ruiz-GimenezLeticia Ruiz-Gimenez More articles by this author , Emilio RiosEmilio Rios More articles by this author , Dario Sánchez-CabreroDario Sánchez-Cabrero More articles by this author , Elisa York PinedaElisa York Pineda More articles by this author , Asier LeibarAsier Leibar More articles by this author , Jose María Alonso-DorregoJose María Alonso-Dorrego More articles by this author , and Luis Martínez-PiñeiroLuis Martínez-Piñeiro More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003290.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Current international guidelines address genetic counseling for patients with Prostate Cancer (PCa) and family history and/or metastatic PCa (mPCa). We aimed to analyze results from males evaluated at our Family Cancer and Genetic Counseling Unit. METHODS: Between 07-2020 and 09-2022, 1472 patients were counseled for genetic testing, of whom 318 (21,6%) were men. Male patients referred by urologists had at least one criteria of: (a) mutation carrier family member, (b) mPCa, (c) PCa and family history of mPCa, (d) high risk PCa <60y and family history of PCa, and (e) PCa <60y and family history of breast or ovarian cancer at <50y.Identified mutations on tested males were recorded as pathogenic, variants of uncertain significance or negative. We analyzed patient and disease characteristics on pathogenic carriers. We reviewed management recommendations of male healthy carriers. RESULTS: Eighty-nine (28%) males had a pathogenic mutation on genetic testing. Fifthy-Five (17%) were related to PCa genetic counseling. We divided carriers into two groups: Group A (healthy carriers) and Group B (oncologic patients with identified pathogenic mutation). Group A (28/55; 51%) were tested due to known family mutation on close blood relatives. Family history was breast cancer in 24 (86%), PCa in 9 (32%), and HOBC in 6 (21%) HBOC. Median age was 41 (range 15-70), and pathogenic mutations were: 4 ATM, 7 BRCA1, 9 BRCA2, 1 MLH1, 2 MUTHY, 5 RAD51D and 1 TP53. Mean PSA was 1,02ng/dl (range 0,32-3,96). All group A patients had follow-up scheduled in Urology Genetic Counseling clinic and General Surgery Breast and Pancreas Cancer Unit. Healthy carriers had adapted PCa screening. Group B (27/55; 49%) patients had cancer: 16 (59%) had PCa, 7 (26%) Colorectal cancer and 4 (15%) other cancers. Median age was 52 (range 39-80). Family history of PCa was present in 13 (48%). Germline pathogenic mutations were found in 25 (93%): 4 ATM, 5 BRCA1, 4 BRCA2, 1 HOXB13, 2 MLH1, 1 MSH2, 1 MUTYH, 3 PALB2, 1 PMS2, 2 RAD51D and 2 TP53. Two patients (7%) had somatic pathogenic mutations. Out of the 16 patients with PCa, 37,5% had mPCa, 31,3% high risk PCa and 31,3% had intermediate risk PCa diagnosed at age <50y and >2 relatives with PCa. Somatic mutations were identified on mPCa. CONCLUSIONS: We found 28% of positive genetic testing in males.Patients with identified pathogenic variants should be recommended close follow-up as some are associated with aggressive PCa.The widespread use of genetic testing in other malignancies (i.e. Breast Cancer, HOBC), will increase healthy carriers. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e620 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Estefania Linares-Espinós More articles by this author Leticia Ruiz-Gimenez More articles by this author Emilio Rios More articles by this author Dario Sánchez-Cabrero More articles by this author Elisa York Pineda More articles by this author Asier Leibar More articles by this author Jose María Alonso-Dorrego More articles by this author Luis Martínez-Piñeiro More articles by this author Expand All Advertisement PDF downloadLoading ...

MP55-16 COMBINATION OF PRE-BIOPSY EXODX TESTING AND mpMRI IMPROVES PREDICTIVE POWER OF HIGH-GRADE PROSTATE CANCER

You have accessJournal of UrologyCME1 Apr 2023MP55-16 COMBINATION OF PRE-BIOPSY EXODX TESTING AND mpMRI IMPROVES PREDICTIVE POWER OF HIGH-GRADE PROSTATE CANCER Andrew Skomra, Adam Russon, K. Kent Chevli, and Sebastian Caraballo Andrew SkomraAndrew Skomra More articles by this author , Adam RussonAdam Russon More articles by this author , K. Kent ChevliK. Kent Chevli More articles by this author , and Sebastian CaraballoSebastian Caraballo More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003308.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: While PSA screening has been instrumental in decreasing prostate cancer (PCa) mortality, it is also not a reliable test for identification of clinically significant Grade Group 2 (GG2) or higher disease. As such, solitary use of PSA for biopsy decision-making can lead to many unnecessary biopsies, over-detection of indolent cancer, or even missing aggressive cases. The ExoDx Prostate Intelliscore test is a non-invasive risk assessment biomarker tool that has been prospectively evaluated for detection of high grade prostate cancer and can help inform whether to proceed with biopsy. We aimed to evaluate the predictive utility for high-grade PCa of ExoDx and whether there is added value when combined with multi-parametric MRI (mpMRI) at our local institution. METHODS: Records of 109 Medicare patients from University at Buffalo urology providers and affiliates who underwent urine ExoDx testing since 2021 were retrospectively reviewed. Most patients did receive mpMRI imaging and all did eventually proceed with systematic prostate biopsies. Those without a “gray-zone” PSA (2-10 ng/mL) and those with prior prostate biopsies were excluded. We analyzed the sensitivity (SE), specificity (SP), and negative and positive predictive values (NPV and PPV) of the ExoDx biomarker, mpMRI, PSAD, and ExoDx+mpMRI combination technique for detection of all prostate cancers and strictly high-grade prostate cancers (defined as Gleason grade 3+4 or higher). ExoDx Intelliscores>15.6, PIRADS 4 or 5 lesions on MRI, and PSAD’s>.15 were considered high prostate cancer risk values. Multivariate logistic regression modeling adjusting for age, PSA, prostate volume, and family history of PCa was then performed to examine each modality’s ability to predict biopsy-proven cancer. Statistical analysis was performed with SPSS with an α of 0.05. RESULTS: 91 of the 109 patients enrolled met inclusion criteria. Mean age was 70.3 years, median PSA was 4.9. ExoDx had the highest sensitivity overall, but the lowest specificity (Table 1). A positive mRI had the highest specificity and positive predictive value for detecting high-grade prostate cancer between ExoDx and PSAD, though with significant sensitivity trade-off to ExoDx. Logistic regression modeling revealed that having a high ExoDx score or PIRADS 4/5 lesion on MRI were strongly associated with finding high-grade PCa (Table 2): ExoDx OR 6.52 (CI 2.87-15.8, p<.01), PIRADS 4/5 OR 13.41 (CI 3.19-41.22, p<.01), PSAD>.15 OR 2.12 (CI 0.63-4.31, p=.38).Combining the ExoDx biomarker with MRI resulted in the best predictive ability for detecting high-grade cancer with an OR of 18.67 (CI 4.54-68.1, p<.01). CONCLUSIONS: mpMRI outperformed both ExoDx and PSAD for detection of high-grade prostate cancer but with considerable trade-off in sensitivity to ExoDx. Incorporating the ExoDx biomarker with MRI resulted in the best predictive ability, suggesting there may be a synergistic detection effect with combination approach. This data suggests MRI alone may not be sufficient in certain cases and that employing the ExoDx test could provide added benefit for both biopsy decision-making and predictive capability. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e770 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Andrew Skomra More articles by this author Adam Russon More articles by this author K. Kent Chevli More articles by this author Sebastian Caraballo More articles by this author Expand All Advertisement PDF downloadLoading ...

MP38-03 DOES PROSTATE CANCER FAMILY HISTORY HAVE AN IMPACT ON ACTIVE SURVEILLANCE ADHERENCE IN MEN WITH LOW- OR FAVOURABLE INTERMEDIATE RISK DISEASE?

You have accessJournal of UrologyCME1 Apr 2023MP38-03 DOES PROSTATE CANCER FAMILY HISTORY HAVE AN IMPACT ON ACTIVE SURVEILLANCE ADHERENCE IN MEN WITH LOW- OR FAVOURABLE INTERMEDIATE RISK DISEASE? Riccardo Leni, Armando Stabile, Giorgio Gandaglia, Vito Cucchiara, Marco Bandini, Elio Mazzone, Leonardo Quarta, Paolo Zaurito, Francesco De Cobelli, Giorgio Brembilla, Nicola Fossati, Lugano, Switzerland, Emanuele Zaffuto, Marco Moschini, Giulio Avesani, Federico Dehò, Francesco Montorsi, and Alberto Briganti Riccardo LeniRiccardo Leni More articles by this author , Armando StabileArmando Stabile More articles by this author , Giorgio GandagliaGiorgio Gandaglia More articles by this author , Vito CucchiaraVito Cucchiara More articles by this author , Marco BandiniMarco Bandini More articles by this author , Elio MazzoneElio Mazzone More articles by this author , Leonardo QuartaLeonardo Quarta More articles by this author , Paolo ZauritoPaolo Zaurito More articles by this author , Francesco De CobelliFrancesco De Cobelli More articles by this author , Giorgio BrembillaGiorgio Brembilla More articles by this author , Nicola FossatiNicola Fossati More articles by this author , Lugano Lugano More articles by this author , Switzerland Switzerland More articles by this author , Emanuele ZaffutoEmanuele Zaffuto More articles by this author , Marco MoschiniMarco Moschini More articles by this author , Giulio AvesaniGiulio Avesani More articles by this author , Federico DehòFederico Dehò More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , and Alberto BrigantiAlberto Briganti More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003276.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Men with family history (FH) of prostate cancer (PCa) on active surveillance (AS) for low grade PCa are at higher risk of reclassification. In these patients, however, adherence to AS may be influenced by factors other than reclassification. We assessed the relationship between FH and AS drop-out without evidence of reclassification compared to patients without FH. METHODS: We identified 779 men on AS for grade group 1 or 2 PCa at our Institution (2005-2021). Reclassification was defined as an increase in Gleason score from diagnosis. The cumulative incidence function estimated the 5-year discontinuation rate without reclassification according to FH (any-degree, vs no FH), with discontinuation for reclassification as a competing event. The Fine and Gray model was used to derive the adjusted sub-distribution hazard ratios (aSHR). A sensitivity analysis was conducted incorporating a definition of volume reclassification (>33% of cores involved or >50% of a single core involved), and the NCCN definition of strong FH (≥1 first-degree or ≥2 second-degree relatives). To assess clinical utility, we evaluated rates of adverse pathology ([AP], grade group ≥2, extracapsular extension, or positive lymph nodes) in 246 men who underwent delayed radical prostatectomy (RP) according to the reason for discontinuation. RESULTS: Median age was 65 years (59-70 yrs), 135 men (18%) had FH, and 112 (14%) had strong FH. Median follow-up was 50 months, the overall 5-year reclassification rate was 42%. The overall 5-year rate of discontinuation without reclassification was 23% (n=118). The cumulative incidence of 5-year discontinuation without reclassification in patients with, vs without FH was 27% vs 15% (aSHR 1.61, p=0.029). The effect of FH on discontinuation without reclassification remained significant in all sensitivity analyses. No difference was observed in terms of AP at delayed RP according to FH in those reclassified vs those treated without reclassification (all p>0.05). CONCLUSIONS: Although FH is associated with higher risk of reclassification, almost a third of men with positive FH discontinue AS without evidence of progression. The absence of a difference in AP rates at delayed RP should guide patient counseling about safety of AS also in men with FH. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e524 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Riccardo Leni More articles by this author Armando Stabile More articles by this author Giorgio Gandaglia More articles by this author Vito Cucchiara More articles by this author Marco Bandini More articles by this author Elio Mazzone More articles by this author Leonardo Quarta More articles by this author Paolo Zaurito More articles by this author Francesco De Cobelli More articles by this author Giorgio Brembilla More articles by this author Nicola Fossati More articles by this author Lugano More articles by this author Switzerland More articles by this author Emanuele Zaffuto More articles by this author Marco Moschini More articles by this author Giulio Avesani More articles by this author Federico Dehò More articles by this author Francesco Montorsi More articles by this author Alberto Briganti More articles by this author Expand All Advertisement PDF downloadLoading ...

MP55-03 CORRELATION BETWEEN PSMA PET/CT DATA AND PATHOLOGICAL TUMOUR STAGING AND GRADING OF PROSTATE CANCER

MP55-03 CORRELATION BETWEEN PSMA PET/CT DATA AND PATHOLOGICAL TUMOUR STAGING AND GRADING OF PROSTATE CANCER

PD21-12 SECOND PRIMARY MALIGNANCY RELATED MORTALITY IN MEN TREATED WITH RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER: AN INSIGHT INTO PROSTATE CANCER SURVIVORSHIP AT 15-YEARS OF FOLLOW-UP

You have accessJournal of UrologyCME1 Apr 2023PD21-12 SECOND PRIMARY MALIGNANCY RELATED MORTALITY IN MEN TREATED WITH RADICAL PROSTATECTOMY FOR LOCALIZED PROSTATE CANCER: AN INSIGHT INTO PROSTATE CANCER SURVIVORSHIP AT 15-YEARS OF FOLLOW-UP Akshay Sood, Ralph Grauer, Mireya Diaz-Insua, Firas Abdollah, and Mani Menon Akshay SoodAkshay Sood More articles by this author , Ralph GrauerRalph Grauer More articles by this author , Mireya Diaz-InsuaMireya Diaz-Insua More articles by this author , Firas AbdollahFiras Abdollah More articles by this author , and Mani MenonMani Menon More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003287.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: A high life-expectancy in men following treatment of prostate cancer (PCa) has brought into focus post-therapy survivorship. In this report, we examined the ultimate cause of death in men with localized PCa treated with upfront radical prostatectomy (RP), with a focus on second primary malignancy (SPM)-related mortality. METHODS: Overall, 6,067 men that underwent robotic RP between September 2001 and December 2013 and were eligible for >5 years of follow-up were included in the study. Patients were stratified by burden of comorbidity (age-adjusted Charlson comorbidity index [aa-CCI]) and postoperative tumor-specific risk (Diaz classification [risk-groups 1-5]), and mortality from PCa, SPM, cardio-cerebrovascular disease, and other/unknown causes was estimated using competing-risk cumulative incidence analysis. RESULTS: The median follow-up was 8.2 years. At 15-years, 2.0% of all patients had died from a SPM. All-cause mortality at 15-years was 7.6%. SPMs were the leading cause of death in healthy men (aa-CCI ≤3) with low-to-intermediate risk disease (Diaz risk-groups ≥3), with 1.1 to 4.4% of these patients dying of SPMs during the study-period. In contrast, only 0.1 to 0.2% of these patients died of PCa and 1.1 to 3.7% of cardio-cerebrovascular disease (Figure). The top three most lethal SPMs were lung, pancreatic, and liver cancers. Standardized mortality ratio (SMR) analysis demonstrated that SPM-related mortality in PCa survivors was higher than that in the general public (2- to 12-fold higher, depending on SPM). Family history of prostate or other cancers and/or use of post-RP radiation/hormone therapy were not associated with increased risk of SPM mortality. CONCLUSIONS: Prostate cancer survivors, especially those in good health, may be at increased risk for death from second primary malignancies and may benefit from tailored cancer screening programs. These data require further validation -- if verified, may have important implications with regards to long-term surveillance of PCa survivors. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e595 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Akshay Sood More articles by this author Ralph Grauer More articles by this author Mireya Diaz-Insua More articles by this author Firas Abdollah More articles by this author Mani Menon More articles by this author Expand All Advertisement PDF downloadLoading ...

MP55-13 BROTHERS LINKED AGAINST CANCER, CANCER EDUCATION PROGRAM ASSESSING PROSTATE CANCER KNOWLEDGE IN AFRICAN AMERICANS UTILIZING FAITH-BASED PARTNERSHIPS

You have accessJournal of UrologyCME1 Apr 2023MP55-13 BROTHERS LINKED AGAINST CANCER, CANCER EDUCATION PROGRAM ASSESSING PROSTATE CANCER KNOWLEDGE IN AFRICAN AMERICANS UTILIZING FAITH-BASED PARTNERSHIPS Crystal Casado, Marcus Moses, Jonathan Allotey, Andrew Anderson, and Spencer Krane Crystal CasadoCrystal Casado More articles by this author , Marcus MosesMarcus Moses More articles by this author , Jonathan AlloteyJonathan Allotey More articles by this author , Andrew AndersonAndrew Anderson More articles by this author , and Spencer KraneSpencer Krane More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003308.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: In the past decade, cancer mortality rates have declined in the United States, however, African-American (AA) men continue to have a two-fold higher prostate cancer (PCa) incidence and mortality compared to their Caucasian counterparts. While there is no apparent etiologic reason for this disparity, AA men continue to experience significant differences in PCa screening measures, treatment decisions, clinical outcomes, and clinical trial enrollment. To address PCa disparities, Brothers Linked Against Cancer (BLAC), a culturally tailored cancer education initiative, aims to equitably empower and enhance AA’s awareness and understanding of PCa through faith-based partnerships. METHODS: In collaboration with AA churches in New Orleans, LA, BLAC organized PCa awareness events targeting AA men and women over thirty years of age. Participants were instructed to watch BLAC’s 6-minute culturally tailored PCa educational video and complete pre- and post-surveys consisting of demographic questions and knowledge assessments composed of 12 questions from the Knowledge of PCa and Screening Scale. Statistical analyses were performed using t-tests with a p-value <0.05 for significance. RESULTS: A total of 51 participants (86% men, 63% age>65, 49% college-educated, 44% retired) attended BLAC PCa awareness events between March-July 2022. Most men (66%) indicated receiving PCa screening before with 29% of participants reporting a family history of PCa. The mean pretest score for all participants was 8 (69%), with the mean posttest score rising to 10 (83%) (p<0.002). After the events, most participants (93%) endorsed comfort in discussing PCa and (84%) planned to talk to their doctor about PCa screening. CONCLUSIONS: In this pilot study, BLAC successfully fostered community engagement, promoted PCa awareness, and increased the understanding of PCa at partnering AA churches. PCa disparities are multidimensional, and complex health interventions, including trust-building, are needed to address them effectively. Source of Funding: Albert Schweitzer Foundation & Center for Public Service (Tulane University) © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e768 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Crystal Casado More articles by this author Marcus Moses More articles by this author Jonathan Allotey More articles by this author Andrew Anderson More articles by this author Spencer Krane More articles by this author Expand All Advertisement PDF downloadLoading ...

A matched case-control study in Taiwan to evaluate potential risk factors for prostate cancer

The rising incidence rate of prostate cancer (PCa) worldwide has become a public health concern. PCa has a multifactorial etiology, and the link between human papillomavirus (HPV) and PCa has been widely investigated by numerous case–control studies. This age-matched, case–control study included 143 PCa patients and 135 benign prostatic hyperplasia (BPH) patients, with prostatic specimens testing negative for malignancy, as control. Study participants were recruited from four major hospitals in Taoyuan City, Taiwan, period 2018–2020, looking into HPV infection and other PCa risk factors, including dietary habits, family history, personal lifestyle, and sexual behavior. Multiple logistic regression analysis and forward stepwise selection analysis were conducted to identify potential risk factors for PCa. HPV DNA was found in 10 of the 143 PCa cases (7%) and 2 of the 135 BPH controls (1.5%) (OR = 6.02, 95% CI = 1.03–30.3, p = 0.046). This association was slightly significant, and furthermore, high risk HPV was not found to be associated with PCa. Higher body mass index (BMI) (OR = 1.15, 95% CI = 1.05–1.27, p = 0.003), more total meat consumption (OR = 2.74, 95% CI = 1.26–5.94, p = 0.011), exhibited association to PCa. However, PCa family history only presented a statistically significant difference by forward stepwise analysis (OR = 3.91, 95% CI = 1.17–13.12, p = 0.027). While much focus has been on the association between HPV and PCa, the results of this study indicate that more efforts should be directed towards investigating dietary habits, personal lifestyle and family history as factors for PCa. These results could serve as a basis for designing PCa prevention strategies.

Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.

Despite family history being an established risk factor for prostate cancer, the role of a broader definition of family history inclusive of not just prostate cancer but other genetically related malignancies has not been investigated in the active surveillance population. Here, we evaluate the impact of an expanded definition of family history on active surveillance outcomes. Patients undergoing active surveillance for prostate cancer at Massachusetts General Hospital from 1997-2019 with detailed data available on family cancer history were identified. Primary outcome was biopsy progression-free survival, and secondary outcomes were treatment-free survival, adverse pathological features at prostatectomy, and biochemical recurrence after treatment. Statistical analyses were conducted using the Kaplan-Meier method and Cox regression. Among 855 evaluable patients, 300 (35.1%) patients had any family history of prostate cancer, and 95 (11.1%) had a family history of related malignancies suggestive of a hereditary cancer syndrome. Family history of prostate cancer alone was not associated with biopsy progression, whereas family history suggestive of a hereditary cancer syndrome was associated with a significantly increased risk of biopsy progression (HR 1.43, 95%CI 1.01-2.02), independent of other known clinicopathological risk factors in multivariable analysis. Similarly, family history suggestive of a hereditary cancer syndrome was associated with significantly lower treatment-free survival (HR 1.58, 95%CI 1.14-2.18) in multivariable analysis. No significant association was found between family history and adverse features on surgical pathology or biochemical recurrence. An expanded family history suggestive of a hereditary cancer syndrome is an independent predictor of biopsy progression during active surveillance. Men with such a family history may still be offered active surveillance but should be counseled regarding the higher risk of disease progression.

Uptake of prostate cancer screening and associated factors among men aged 50 years and above in Lira city, Uganda: a cross-sectional study

BackgroundProstate cancer is the most common cancer among men globally, with over 1.2 million cases reported in 2018. About 90% of men with prostate cancer are diagnosed when the disease is in an advanced stage. We assessed the factors associated with the uptake of prostate cancer screening among men aged ≥ 50 years in Lira city.MethodsThis was a cross-sectional study involving 400 men aged ≥ 50 years in Lira city who were sampled using multistage cluster sampling method. Uptake of prostate cancer screening was defined as the proportion of men who received prostate cancer screening in the past one year prior to the interview. Multivariable logistic regression analyses were performed to assess the factors associated with the uptake of prostate cancer screening. Data were analyzed using Stata version 14.0 statistical software.ResultsOf the 400 participants, only 18.5% (74/400) had ever been screened for prostate cancer. However, 70.7% (283/400) were willing to screen/rescreen if provided with the opportunity. Majority of the study participants, 70.5% (282/400) had ever heard about prostate cancer, mostly from a health worker (40.8% (115/282)). Less than half of the participants had high knowledge of prostate cancer. The factors that were significantly associated with prostate cancer screening were age ≥ 70 years, Adjusted Odds Ratio (AOR) 3.29: 95% Confidence Interval (CI): 1.20-9.00) and having a family history of prostate cancer, AOR 2.48 (95%CI: 1.32–4.65).ConclusionThere was low uptake of prostate cancer screening among men in Lira City, but majority of men were willing to screen. We encourage policymakers in Uganda to ensure prostate cancer screening services are readily available and accessible by men so as to improve on early identification and treatment of the disease.

Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.

Germline testing for prostate cancer is on the increase, with clinical implications for risk assessment, treatment, and management. Regardless of family history, NCCN recommends germline testing for patients with metastatic, regional, very-high-risk localized, and high-risk localized prostate cancer. Although African ancestry is a significant risk factor for aggressive prostate cancer, due to a lack of available data no testing criteria have been established for ethnic minorities. Through deep sequencing, we interrogated the 20 most common germline testing panel genes in 113 Black South African males presenting with largely advanced prostate cancer. Bioinformatic tools were then used to identify the pathogenicity of the variants. After we identified 39 predicted deleterious variants (16 genes), further computational annotation classified 17 variants as potentially oncogenic (12 genes; 17.7% of patients). Rare pathogenic variants included CHEK2 Arg95Ter, BRCA2 Trp31Arg, ATM Arg3047Ter (2 patients), and TP53 Arg282Trp. Notable oncogenic variants of unknown pathogenicity included novel BRCA2 Leu3038Ile in a patient with early-onset disease, whereas patients with FANCA Arg504Cys and RAD51C Arg260Gln reported a family history of prostate cancer. Overall, rare pathogenic and early-onset or familial-associated oncogenic variants were identified in 6.9% (5/72) and 9.2% (8/87) of patients presenting with a Gleason score ≥8 or ≥4 + 3 prostate cancer, respectively. In this first-of-its-kind study of southern African males, we provide support of African inclusion for advanced, early-onset, and familial prostate cancer genetic testing, indicating clinical value for 30% of current gene panels. Recognizing current panel limitations highlights an urgent need to establish testing guidelines for men of African ancestry. We provide a rationale for considering lowering the pathologic diagnostic inclusion criteria and call for further genome-wide interrogation to ensure the best possible African-relevant prostate cancer gene panel.

Abstract PD14-06: PD14-06 Polygenic risk score added to risk calculator improves prediction of breast cancer in U.S. Black women

Abstract We recently derived an absolute breast cancer risk prediction model, the Black Women’s Health Study (BWHS) model, for breast cancer in U.S. Black women using data from three large case-control studies and validated it in independent prospective data from the Black Women’s Health Study (Palmer 2021). The BWHS model includes epidemiologic risk factors as well as family history of breast cancer and family history of prostate cancer. It does not include genetic variants because at the time of model development breast cancer polygenic risk scores performed poorly in women of predominantly African ancestry, primarily due to differences in allele frequency and linkage disequilibrium. More recently, Gao et al. (2022) developed and tested a polygenic risk score (PRS) using 56,943 SNPs for breast cancer in women of African ancestry (AA) based on 9,235 breast cancer cases and 10,184 controls from a large pooled analysis of studies from African American and African women; the c-statistic from cross-validation was 0.581, considerably better than in previous efforts. We evaluated whether adding this AA-PRS to the BWHS risk prediction model would improve risk stratification. We conducted a nested case-control study of 901 breast cancer cases and 1,576 controls matched on age and most recent questionnaire completed from among BWHS participants for whom genome-wide association data were available and who had not been included in the collaboration from which the PRS was derived and tested. We examined discriminatory accuracy, estimated by the area under the receiver operating characteristic curve (AUC), for the risk prediction model alone, the PRS alone, and the combination of risk prediction model and PRS, controlling for the matching factor “questionnaire cycle”. We conducted the analyses within strata of 5-year age and then combined results using inverse-variance weighting. In preliminary analyses, the AUC was 0.579 for the risk prediction model alone and 0.600 for the AA-PRS alone. When the AA-PRS and the BWHS risk prediction model were both used as predictors in a logistic regression model, the AUC increased from 0.579 to 0.622. This improvement in risk stratification is similar to what Kachuri et al. (2020) obtained in an analysis of U.K. Biobank data, where adding a PRS to epidemiologic and personal risk factors showed an improvement from 0.572 to 0.635 in women of European ancestry. The present study provides external validation of a recently derived AA PRS and demonstrates the potential for improving risk stratification for U.S. Black women by adding a PRS to a breast cancer risk prediction model that already includes family history of breast cancer. Citation Format: Gary R. Zirpoli, Kathryn L. Lunetta, Ruth M. Pfeiffer, Julie R. Palmer. PD14-06 Polygenic risk score added to risk calculator improves prediction of breast cancer in U.S. Black women [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD14-06.

Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).

99 Background: A subset of pts with metastatic prostate cancer have HRR mutations. These can be either germline or somatic mutations. Previous studies have established a prognostic and predictive role of HRR mutations and there are ongoing trials (e.g., TALAPRO-3, AMPLITUDE) exploring combination strategies of poly-ADP ribose polymerase inhibitors (PARPi) with novel hormonal therapies (NHT). Therefore, it is relevant to establish baseline HRR testing rates in the real-world setting. This study assessed real-world (rw) HRR testing patterns in pts with mCSPC in the US and described characteristics of tested vs untested pts. Methods: Data were drawn from the Adelphi Prostate Cancer Disease Specific Programme; a point-in-time questionnaire administered to oncologists and urologists in the US between January-August 2020. Physicians abstracted medical records for the next 4-9 pts receiving active drug treatment for mCSPC. Study variables included pt demographics, clinical factors, physician characteristics, and testing status for at least 1 of 12 HRR genes of interest ( ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C). Pt demographics and clinical characteristics were compared between groups using t-tests for continuous and chi-squared or Fisher’s exact test for categorical variables. A multiple logistic regression model was used to assess factors associated with odds of HRR testing. Results: A total of 71 physicians reported on 204 pts with mCSPC. The median age was 68.8. 57/204 (28%) pts were tested for HRR mutations using germline or tumor testing. Pts who were not HRR tested were older compared to HRR tested pts (69.6 vs 66.8, P = 0.038). More pts currently receiving care by an oncologist had a HRR mutation test vs. pts currently receiving care by a urologist [50/156 (32%) vs 7/48 (15%), P =0.02]. According to the multiple logistic regression model, having a known family history of prostate cancer [OR = 3.9 (95% CI: 1.1 – 13.6); P = 0.04], and having visceral metastases at mCSPC diagnosis [OR=4.9 (95% CI: 2.0 – 12.1); P = 0.001] were associated with a significantly higher odds of receiving a HRR mutation test. Conclusions: In this rw US study of adult patients with mCSPC, most patients did not receive HRR testing. Disparities in HRR mutation testing were observed, suggesting that clinical characteristics may influence decisions to test for HRR mutations. Focused efforts to increase HRR mutation testing should be implemented.

A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.

266 Background: The frequency of young men with aggressive prostate cancer (PC) at diagnosis is increasing. Clinical, environmental, and genetic drivers of this change have not been well characterized. Methods: This multi-institutional study evaluated two cohorts; Cohort 1 completed enrollment and is reported here. Eligible patients (pts) had early-onset (age ≤ 60 years) PC with metastasis (N+ or M+) at diagnosis, or within 5 years of curative intent local therapy. Data were collected to define clinical, environmental, and genetic profiles, including ctDNA and whole genome and transcriptome sequencing using Tempus xE. Standard descriptive statistics were used. Results: 46 pts were enrolled. Median age at diagnosis was 55 (range 41-60 years); 85% were White, 15% were Black; 4% served in the military and 4% reported biochemical exposure. 85% reported a family history of cancer, 46% had family history of PC. Median PSA at diagnosis was 19 (range 1-534 ng/mL), 56% had a Gleason score of 9-10, and 56% had de novo metastatic PC. 46% had prior local therapy. Genetic data is available for 40 pts. The most frequent clinically significant mutations (≥10% for somatic, ≥2.5% for germline) are summarized. 23 unique germline and over 1,000 unique somatic mutations were identified. Germline mutations associated with hereditary PC were found in 15%, all were associated with DNA damage repair (DDR). Somatic mutations in DDR genes were found in 10%. Co-mutations in TP53 and BRAF were seen in 30%. Interestingly, there were also incidental germline mutations identified that are associated with cardiac ( MYBPC, MYH7) and vascular ( MYH11, ACTA2) conditions, among others. Conclusions: In this cohort study we identified an unexpectedly high frequency of family histories that were positive for cancer (85%), and specifically PC (46%). However, rates of germline mutations associated with hereditary PC were similar to previous studies (15%), suggesting the possibility that other novel hereditary mutations driving increased PC risk may be present. Increased rates of somatic mutations in BRAF (35%) were also seen. The high frequency of BRAF mutations, particularly those that co-occur with TP53 mutations, may be driving more aggressive disease. We also found enrichment of mutations associated with non-cancer hereditary syndromes, including hypertrophic cardiomyopathy. These are not usually included in cancer-focused genetic studies, suggesting broader testing that includes potentially actionable incidental findings should be considered. More work is needed to define characteristics of this high-risk population and optimize management. [Table: see text]

Does prostate cancer family history have an impact on active surveillance adherence in men with low- or favourable intermediate risk disease?

Does prostate cancer family history have an impact on active surveillance adherence in men with low- or favourable intermediate risk disease?

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting

BackgroundGermline and tumour genetic testing in prostate cancer (PCa) is becoming more broadly accepted, but testing indications and clinical consequences for carriers in each disease stage are not yet well defined. ObjectiveTo determine the consensus of a Dutch multidisciplinary expert panel on the indication and application of germline and tumour genetic testing in PCa. Design, setting, and participantsThe panel consisted of 39 specialists involved in PCa management. We used a modified Delphi method consisting of two voting rounds and a virtual consensus meeting. Outcome measurements and statistical analysisConsensus was reached if ≥75% of the panellists chose the same option. Appropriateness was assessed by the RAND/UCLA appropriateness method. Results and limitationsOf the multiple-choice questions, 44% reached consensus. For men without PCa having a relevant family history (familial PCa/BRCA-related hereditary cancer), follow-up by prostate-specific antigen was considered appropriate. For patients with low-risk localised PCa and a family history of PCa, active surveillance was considered appropriate, except in case of the patient being a BRCA2 germline pathogenic variant carrier. Germline and tumour genetic testing should not be done for nonmetastatic hormone-sensitive PCa in the absence of a relevant family history of cancer. Tumour genetic testing was deemed most appropriate for the identification of actionable variants, with uncertainty for germline testing. For tumour genetic testing in metastatic castration-resistant PCa, consensus was not reached for the timing and panel composition. The principal limitations are as follows: (1) a number of topics discussed lack scientific evidence, and therefore the recommendations are partly opinion based, and (2) there was a small number of experts per discipline. ConclusionsThe outcomes of this Dutch consensus meeting may provide further guidance on genetic counselling and molecular testing related to PCa. Patient summaryA group of Dutch specialists discussed the use of germline and tumour genetic testing in prostate cancer (PCa) patients, indication of these tests (which patients and when), and impact of these tests on the management and treatment of PCa.

Usefulness of podcasts to provide public education on prostate cancer genetics.

Podcasts, or episodic digital audio recordings, represent a novel way to reach large audiences for public education. Genetic evaluation has important implications for prostate cancer (PCa) care but is underutilized. We created a series of five podcasts about PCa genetics and tested their usefulness in raising awareness and providing education to lay audiences. We recruited 157 men and women from the general public and 100 patients with PCa from across the U.S., who listened to a podcast and completed an online survey. The primary outcome was the perceived usefulness of the podcast (score ≥5 on a published 7-point Likert scale). Secondary outcomes were relevance to informational needs, satisfaction and ease of use, as well as genetic knowledge and attitudes toward genetic testing after listening to the podcasts. The podcasts were associated with high mean scores for perceived usefulness (5.6/7), relevance to informational needs (5.6/7), satisfaction (5.8/7), and ease of use (5.9/7). After listening to the podcasts, 80-100% correctly answered most key knowledge questions about PCa genetics, and 85% had a positive attitude toward genetic testing. On multivariable analysis, the perceived usefulness of the podcasts was higher among Black/Hispanic adults (p = 0.05) and those with a family history of PCa (p = 0.01). A podcast series on PCa genetics was perceived as useful and associated with high rates of knowledge for patients with PCa and the general public. Podcasts represent a promising new educational tool to raise awareness about PCa genetic evaluation, particularly for high-risk groups.

Abstract A077: Are anthropometric measures associated with prostate cancer in Nigerian men?

Abstract Purpose/Objective(s): Despite prostate cancer (PCa) being a public health problem globally, much remains unknown of its etiology. Though obesity is a probable risk factor for prostate cancer measurable by anthropometric indices, its impact on PCa development with other risk factors has not been explored among Nigerian men. This study was designed to test the hypothesis that anthropometric indices are higher in prostate cancer patients compared to age-matched healthy controls. Materials/Methods: The study was a case-control study conducted in four tertiary hospitals in Nigeria. The cases were newly diagnosed prostate cancer patients, while the controls were age-matched healthy men confirmed to be cancer-free with normal PSA. Patients with weight loss (self-reported) in the past month, ECOG ≥3, and uncontrolled comorbidities (diabetes and hypertension) were not eligible. Socio-demographics (age, marital status, ethnicity, the highest level of education, occupation, and employment status) and clinical history (high-fat diet, physical activity, cigarette smoking, alcohol, family history of prostate cancer, and Gleason score [for cases]) using an interviewer-administered questionnaire, and anthropometric measures (weight, height, body mass index, waist circumference, hip circumference, and waist-hip ratio [WHR]) physically measured were obtained from all participants. The socio-demographics and the clinical history were compared between cases and controls using a chi-square test. The comparison of the anthropometric measures between the groups and their correlation with Gleason's score were determined using a t-test. Results: Seventy-three prostate cancer cases (PCa) and seventy-three age-matched healthy controls (Co) were recruited for the study. The mean age was 64.20 years (SD = 6.184). Only the mean WHR was of significant difference between the PCa and the Co (0.98 [SD=0.07] PCa: 0.93 [SD=0.06] Co, p=&amp;lt;0.0001). Forty-three (58.9%) of the cases had high-grade diseases (Gleason Score 8-10). No significant association was found between anthropometric indices and the disease grade. PCa and Co groups differ by regular exercise (32PCa [43.8%]:47Co [64.4%]; p=0.013), family history of PCa (14PCa [19.2%]:2Co [2.7%]; p=0.001), tobacco smoking (28PCa [38.4%]:15Co [20.5%]; p=0.018), and alcohol consumption (57PCa [78.1%]:43Co [58.9%]; p=0.013). Conclusion: Patients with PCa had higher WHR and were more likely physically inactive, have a family history of prostate cancer, smoke tobacco, or drink alcohol. PCa in Nigerian men are predominantly high-grade, and there was no association between Gleason grade and anthropometric indices. Citation Format: Kehinde O. Adeyinka. Are anthropometric measures associated with prostate cancer in Nigerian men? [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr A077.

Abstract P035: Associations between meat and fish intake and aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP)

Abstract Objective: Results of studies examining the association between intake of meat or fish and prostate cancer have been mixed. However, few of the previous studies have included a racially diverse population or focused on aggressive prostate cancer. We aimed to examine the association between intake of meat and fish and aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project, a case-only study of Black and White men in the United States. Methods: Meat and fish intakes in the year prior to diagnosis were estimated using an interviewer-administered modified version of the National Cancer Institute Diet History Questionnaire in 909 Black and 991 White men with a recent histologically confirmed diagnosis of prostate cancer. High aggressive prostate cancer (n=332) was defined as Gleason sum ≥8, or PSA&amp;gt; 20ng/ml, or Gleason sum ≥7 AND clinical stage T3-T4, and the comparison group was all other prostate cancer cases (n=1,568). Logistic regression was used to determine the odds ratio (OR) and 95% confidence intervals (95% CI) for high aggressive prostate cancer by tertile of meat and fish intake variables, with adjustment for age, energy intake, race, study site, education, family history of prostate cancer, prostate cancer screening history, Charlson comorbidity index, NSAIDs use, smoking status, alcohol intake, and intake of vegetables, fruits, and milk. Results: We observed increased odds of aggressive prostate cancer among men in the second tertile compared to the first tertile for total red meat (OR:1.23. 95% CI: 0.91 – 1.68) and unprocessed red meat (OR:1.30. 95% CI: 0.96 – 1.76), though confidence intervals were imprecise and associations in the top tertile were weaker. For processed meat, a non-statistically significant increased odds of aggressive prostate cancer was observed among men in the third tertile compared to the first tertile (OR:1.27. 95% CI: 0.91 – 1.78). ORs for higher intake of fish and poultry were in the inverse direction but were weak and not statistically significant. Conclusions: In this racially diverse case-only study, we observed weak positive associations between red and processed meat and aggressive prostate cancer, and little evidence of an association with fish or poultry intake. While high temperature cooking and charring of meat is known to increase carcinogen formation, one limitation of our study was the lack of information on cooking methods or doneness of the meat consumed. Additional research is warranted among racially diverse populations that considers cooking methods and doneness preferences. Citation Format: Jessica Sainyo, Susan E. Steck, L. Joseph Su, Lenore Arab, Jeannette T. Bensen, Elizabeth T.H. Fontham, James L. Mohler. Associations between meat and fish intake and aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP). [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): Abstract nr P035.

Abstract IA023: Creating a single cell and spatial atlas of breast, ovarian and prostate cancer for African ancestry

Abstract The US Black population is composed of both US born Black and immigrant Black populations from the Caribbean and Africa. Normal tissues in Black individuals independent of their country of birth or residence is woefully understudied. Black individuals disproportionately develop aggressive pathologic diseases which are treatment refractory or resistant, leading to premature deaths. In women, breast cancer is the most common cancer in Black women in the US, most common non-viral driven cancer in women in Africa and the Caribbean. Black women develop this disease younger than other ancestral groups and have higher incidence of metaplastic and triple negative breast cancer - aggressive pathologies. Ovarian cancer is rare in US-born Black (USB) while in both West and East Africa and the Caribbean, ovarian cancer is more common with more serous pathologies and earlier onset. While the incidence of prostate cancer among Black men in the US is declining, it is increasing in the Caribbean and Africa. Black men disproportionately develop prostate cancer young, have strong family history of prostate cancer, develop aggressive pathologies that are usually refractory to standard of care therapies. With the African-Caribbean Cancer Consortium (AC3) and Transatlantic Gynecologic Cancer Research Consortium, a single cell atlas of the cells of origin and tumors of breast, ovarian and prostate cancer will be constructed from samples across West and East Africa, the Caribbean and the USA in Black individuals. Pairing this single cell atlas with spatial approaches, we hope to develop a benchmark to confidently measure and interpret ancestral genomic differences at the cellular level. In this session, we will discuss how we are using these approaches to look at the relationship between African ancestry, aggressive disease biology, early onset warrants us to study the tissue composition, the proportion of sub-populations that are thought to give rise to tumors and the interplay with germline genetics. Citation Format: Jasmine Plummer. Creating a single cell and spatial atlas of breast, ovarian and prostate cancer for African ancestry [abstract]. In: Proceedings of the 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2022 Sep 16-19; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr IA023.